Compare Gilead Sciences, Inc. (GILD) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Ryanair Holdings plc — how do they compare? Gilead Sciences, Inc. trades at $135.88 (market cap $163.51B), while Ryanair Holdings plc trades at $66.44 (market cap $31.83B). The key difference: Gilead Sciences, Inc. is far larger — about 5.1× Ryanair Holdings plc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | RYAAY | |
|---|---|---|
Market Cap | $163.51B | $31.83B |
Sector | Health | Industrials |
52-Week High | $155.80 | $73.82 |
52-Week Low | $108.22 | $53.24 |
Enterprise Value | $178.05B | $29.49B |
Dividend Yield | 2.49% | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
RYAAY trades at $66.29, up 3.11% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 14.32, net income margin of 13.98%, and consistent earnings beats. Recent news highlights passenger growth and operational updates, though a window incident adds scrutiny. Cash flow remains positive from operations at $3.42B despite negative net cash flow.
Outlook is positive with analyst consensus at 62.5% buy ratings. Revenue growth to $15.5B projected for 2026 supports upside, but risks include fuel cost volatility and regulatory pressures. The stock's valuation and profitability metrics present an attractive entry for long-term investors amid sector recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
